Cooley advised Slate Medicines, a biotechnology company developing next-generation therapeutics for the treatment of migraine, on its definitive agreement to combine with Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, in an all-stock reverse merger transaction.